سامانه مدیریت نشریات علمی دانشگاه علوم پزشکی مشهد

Li, Xiaoying, Yao, Yuanzhi, Wei, Lin. (1402). Indirubin alleviates CCl4-induced liver fibrosis by regulation of TGF-β-mediated signaling pathways. , 26(9), 1047-1052. doi: 10.22038/ijbms.2023.70476.15319
Xiaoying Li; Yuanzhi Yao; Lin Wei. "Indirubin alleviates CCl4-induced liver fibrosis by regulation of TGF-β-mediated signaling pathways". , 26, 9, 1402, 1047-1052. doi: 10.22038/ijbms.2023.70476.15319
Li, Xiaoying, Yao, Yuanzhi, Wei, Lin. (1402). 'Indirubin alleviates CCl4-induced liver fibrosis by regulation of TGF-β-mediated signaling pathways', , 26(9), pp. 1047-1052. doi: 10.22038/ijbms.2023.70476.15319
Li, Xiaoying, Yao, Yuanzhi, Wei, Lin. Indirubin alleviates CCl4-induced liver fibrosis by regulation of TGF-β-mediated signaling pathways. , 1402; 26(9): 1047-1052. doi: 10.22038/ijbms.2023.70476.15319

Indirubin alleviates CCl4-induced liver fibrosis by regulation of TGF-β-mediated signaling pathways

Iranian Journal of Basic Medical Sciences
مقاله 8، دوره 26، شماره 9، آذر 2023، صفحه 1047-1052    اصل مقاله (623.48 K)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.22038/ijbms.2023.70476.15319
نویسندگان
Xiaoying Li1؛ Yuanzhi Yao1؛ Lin Wei* 1، 2، 3
1College of Biology and Food Engineering, Huaihua University. Key Laboratory of Research and Utilization of Ethnomedicinal Plant Resources of Hunan Province, Hunan, 418000, China
2College of Basic Medicine, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China
3Daosheng Biology (Shenzhen) Co., Ltd, Shenzhen, 518107, China
چکیده
Objective(s): Liver fibrosis is a common liver disease caused by chronic liver damage. However, there are currently no approved drugs available to treat it. Therefore, the therapeutic effect of indirubin on liver fibrosis was evaluated. This study investigated the protective effect and related molecular mechanism of indirubin against CCl4-induced liver fibrosis in mice.
Materials and Methods: We first detected the effect of indirubin on liver fibrosis in mice (n=8 per group, 32 mice total) by ELISA, HE, and Masson staining. Subsequently, the proliferation of activated HSCs was detected by MTT and EdU. Finally, the changes of related proteins and signaling pathways in mice treated with indirubin were investigated by qRT-PCR and Western blot. One-way ANOVA or two-tailed student’s t-test was used for comparison between groups.
Results: Firstly, we found that indirubin (25 mg/kg) therapy could attenuate liver injury and significantly down-regulate α-SMA (P=0.0038) and collagen 1 (P=0.0057) in the liver using CCl4-induced liver fibrosis in mice. Secondly, we showed that indirubin (25 μM) could significantly inhibit hepatic stellate cell (HSC) trans-differentiation into myofibroblasts and proliferation (P=0.0063) in HSC-T6 cells treated by TGF-β. Finally, we showed that indirubin could greatly reduce the protein levels of p-Smad2/3, p38, p-ERK, and p-JNK in vivo and in vitro.
Conclusion: Our results suggested that indirubin alleviated liver fibrosis and HSC activation mainly through TGF-β-mediated signaling pathways in vivo and in vitro. In conclusion, our data showed that indirubin could be a promising clinical therapeutic drug for the prevention and treatment of liver fibrosis.
کلیدواژه‌ها
CCl4؛ Fibrosis؛ Indirubin؛ Liver؛ Mouse؛ TGF-β
سایر فایل های مرتبط با مقاله
مراجع
1. Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol 2021; 18: 151-166.
2. Loft A, Alfaro AJ, Schmidt SF, Pedersen FB, Terkelsen MK, Puglia M, et al. Liver-fibrosis-activated transcriptional networks govern hepatocyte reprogramming and intra-hepatic communication. Cell Metab 2021; 33: 1685-1700.
3. Li J, Wang Y, Ma M, Jiang SH, Zhang XL, Zhang YL, et al. Autocrine CTHRC1 activates hepatic stellate cells and promotes liver fibrosis by activating TGF-beta signaling. EBioMedicine 2019; 40: 43-55.
4. Yu HX, Yao Y, Bu FT, Chen Y, Wu YT, Yang Y, et al. Blockade of YAP alleviates hepatic fibrosis through accelerating apoptosis and reversion of activated hepatic stellate cells. Mol Immunol 2019; 107: 29-40.
5. Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med 2019; 65: 37-55.
6. Chen Q, Zhang H, Cao Y, Li Y, Sun S, Zhang JP, et al. Schisandrin B attenuates CCl4-induced liver fibrosis in rats by regulation of Nrf2-ARE and TGF-beta/Smad signaling pathways. Drug Des Devel Ther 2017; 11: 2179-2191.
7. Yan Y, Zeng J, Xing L, Li C. Extra- and intra-cellular mechanisms of hepatic stellate cell activation. Biomedicines 2021; 9: 1014-1031. 
8. Budi EH, Schaub JR, Decaris M, Turner S, Derynck R. TGF-beta as a driver of fibrosis: Physiological roles and therapeutic opportunities. J Pathol 2021; 254: 358-373.
9. Samarakoon R, Overstreet JM, Higgins PJ. TGF-beta signaling in tissue fibrosis: Redox controls, target genes and therapeutic opportunities. Cell Signal 2013; 25: 264-268. 
10. Maity S, Muhamed J, Sarikhani M, Kumar S, Ahamed F, Spurthi KM, et al. Sirtuin 6 deficiency transcriptionally up-regulates TGF-beta signaling and induces fibrosis in mice. J Biol Chem 2020; 295: 415-434.
11. Jia D, Duan F, Peng P, Sun LL, Liu XJ, Wang L, et al. Up-regulation of RACK1 by TGF-beta1 promotes hepatic fibrosis in mice. PLoS One 2013; 8: e60115.
12. Acharya P, Chouhan K, Weiskirchen S, Weiskirchen R. Cellular mechanisms of liver fibrosis. Front Pharmacol 2021; 12: 671640.
13. Schuppan D, Ashfaq-Khan M, Yang AT, Kim YO. Liver fibrosis: Direct antifibrotic agents and targeted therapies. Matrix Biol 2018; 68: 435-451.
14. Rao S, Zaidi S, Banerjee J, Jogunoori W, Sebastian R, Mishra B, et al. Transforming growth factor-beta in liver cancer stem cells and regeneration. Hepatol Commun 2017; 1: 477-493.
15. Luo H, Li L, Tang J, Zhang FX , Zhao F, Sun D, et al. Amygdalin inhibits HSC-T6 cell proliferation and fibrosis through the regulation of TGF-β/CTGF. Mol Cell Toxicol 2016; 12: 265-271.
16. Wang Q, Yu J, Hu Y, Chen XY, Zhang L, Pan T, et al. Indirubin alleviates bleomycin-induced pulmonary fibrosis in mice by suppressing fibroblast to myofibroblast differentiation. Biomed Pharmacother 2020; 131: 110715.
17. Sun B, Wang J, Liu L, Mao L, Peng L, Wang Y. Synthesis and activity of novel indirubin derivatives. Chem Biol Drug Des 2021;97: 565-571.
18. Kim SH, Choi SJ, Kim YC, Kuh HJ. Anti-tumor activity of noble indirubin derivatives in human solid tumor models in vitro. Arch Pharm Res 2009; 32: 915-922. 
19. Xiao Z, Hao Y, Liu B, Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma 2002; 43: 1763-1768.
20. Chen L, Wang J, Wu J, Zheng Q, Hu J. Indirubin suppresses ovarian cancer cell viabilities through the STAT3 signaling pathway. Drug Des Devel Ther 2018; 12: 3335-3342.
21. Ye BY, Shen WL, Zhang CY, Yu ML, Ding XR, Yin M, et al. The role of ZNF143 overexpression in rat liver cell proliferation. BMC Genomics 2022; 23: 483.
22. Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: Mechanistic concepts and therapeutic perspectives. Cells 2020; 9: 875-918.
23. Dobie R, Wilson-Kanamori JR, Henderson BEP, Smith JR, Matchett KP, Portman JR, et al. Single-cell transcriptomics uncovers zonation of function in the mesenchyme during liver fibrosis. Cell Rep 2019; 29: 1832-1847.
24. Iwaisako K, Jiang C, Zhang M, Cong M, Moore-Morris TJ, Park TJ, et al. Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci U S A 2014; 111:E3297-3305.
25. Kuang M, Wu H, Hu L, Guo XY, He DC, Liu B, et al. Up-regulation of FUT8 inhibits TGF-beta1-induced activation of hepatic stellate cells during liver fibrogenesis. Glycoconj J 2021; 38: 77-87.
26. Zhang Y, Song L, Li J, Zhang Y, Lu X, Zhang B. Inhibitory effects of indirubin-3’-monoxime against human osteosarcoma. IUBMB Life 2019; 71: 1465-1474.
27. Rajagopalan P, Dera A, Abdalsamad MR, Chandramoorthy HC. Rational combinations of indirubin and arylidene derivatives exhibit synergism in human non-small cell lung carcinoma cells. J Food Biochem 2019; 43: e12861.

آمار
تعداد مشاهده مقاله: 890
تعداد دریافت فایل اصل مقاله: 716